Compounds > enzastaurin
Page last updated: 2024-09-05

enzastaurin and N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide

enzastaurin has been researched along with N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide in 1 studies

Compound Research Comparison

Studies
(enzastaurin)		Trials
(enzastaurin)		Recent Studies (post-2010)
(enzastaurin)		Studies
(N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide)		Trials
(N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide)		Recent Studies (post-2010) (N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide)
188529916014

Protein Interaction Comparison

ProteinTaxonomyenzastaurin (IC50)N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide (IC50)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)0.3162
Mitogen-activated protein kinase 8Homo sapiens (human)0.2
Mitogen-activated protein kinase 9Homo sapiens (human)0.2581
Mitogen-activated protein kinase 10Homo sapiens (human)0.1998
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)0.3162
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)0.3162
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)0.3162
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)0.3162
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)0.3162
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)0.3162

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1

Other Studies

1 other study(ies) available for enzastaurin and N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013